Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Japan Wholesaler Chief Suzuki to Become IFPW Vice Chairman
September 16, 2016
- Japan Needs Listing Rule Conditional on Possible Ad-Hoc Re-Pricing: Kono
September 7, 2016
- Kenporen’s Kono Pushes for “Huge Seller” Re-Pricing for Opdivo before 2018
September 7, 2016
- Hodanren Demands Ad-Hoc Re-Pricing for Opdivo
September 7, 2016
- Economists, Industry and Regulatory Officials Talk over Pricy Med Issue at JPMA Seminar
September 6, 2016
- JMA Think Tank Calls for Rewarding Innovation with Subsidies, in Lieu of Pricing
September 1, 2016
- Drug Wholesalers See 8.3% Boost in Sales on Hep C Demand: JPWA
August 17, 2016
- JPMA Calls for Financial Support to Encourage R&D on Treatments for ARIs
August 15, 2016
- Sales Rep Number in Japan Logs Big Drop for 2nd Straight Year: Survey
August 12, 2016
- EFPIA Japan Calls for Relaxation of Japanese Vaccine Regulations: Vaccine Subcommittee Head
August 9, 2016
- NPO Petitions Academic Society to Clarify Reason for Deaths Associated with Xeplion
July 20, 2016
- Japan Biosimilar Association Up and Running with Four Member Firms
July 19, 2016
- JPMA Keen to Defend R&D Tax Credit System
July 8, 2016
- Generic Use Rate at 55.7% in FY2015, Up 3.7 Points: JGA
July 8, 2016
- EFPIA Japan Calls for Diversifying Vaccine Supply Sources to Prepare for Crises
July 7, 2016
- Drug Damage Watchdog Challenges Doctors’ View, Says HPV Vaccination Shouldn’t Be Recommended
July 5, 2016
- JMA Vice President Nakagawa Calls for Rules on Use of “Expensive Drugs”
June 27, 2016
- Yokokura Reelected for Third Term as JMA President
June 27, 2016
- NPO Asks MHLW to Take Steps to Ensure Proper Use of Xeplion
June 23, 2016
- PMDA Chief Brings Together Drug Makers, Tech Vendors to Compile Proposal on Digital Health
June 17, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…